ArticleJournal of inflammation research2026
Diagnostic and Prognostic Value of miR-574-3p in Acute Pancreatitis: Insights from Bioinformatics and in vitro Studies.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MicroRNA (miRNA) exists great potential as a biomarker for various diseases. Purpose: This study aimed to explore the role and mechanism of miR-574-3p in acute pancreatitis (AP) to improve clinical management. Patients and Methods: Clinical data from 241 AP patients (87 mild (MAP), 154 moderate-severe (M/SAP)) and 77 healthy controls were analyzed. Dysregulated miRNAs were screened via GEO, with expression levels quantified by qRT-PCR. The miR-574-3p value in AP was assessed via ROC curves, correlation analysis, and multivariate logistic regression. Caerulein-induced HPDE6-C7 cell models were employed to evaluate the effects of miR-574-3p on proliferation, oxidative stress, and inflammation. Luciferase assays confirmed miR-574-3p/EGFR interaction. Results: MiR-574-3p was downregulated in AP and lower in M/SAP than in MAP patients, demonstrating its diagnostic utility. MiR-574-3p was negatively associated with AP severity as evidenced by its correlation with the scoring systems, including Ranson, APACHE II, and SOFA, and served as a risk factor for poor prognosis of M/SAP. In vitro, miR-574-3p overexpression promoted cell proliferation, reduced oxidative stress (decreased MDA, increased SOD), and suppressed inflammation (IL-6, IL-1β, TNF-α) in caerulein-stimulated HPDE6-C7 injury model. EGFR was identified as a downstream gene of miR-574-3p, and its upregulation reversed the protective effects of miR-574-3p. Conclusion: MiR-574-3p, associating with AP severity, served as a diagnostic biomarker for AP and M/SAP. MiR-574-3p was identified as a risk factor for the poor prognosis of M/SAP and involved in pancreatic cell injury through regulating EGFR. This work highlighted the clinical potential of miR-574-3p for AP diagnosis, prognosis and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.